FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087533562> ?p ?o ?g. }

• W2087533562 abstract "Brentuximab vedotin (BV), an antibody-drug conjugate that targets CD30, induces high response rates in CD30(+) lymphoid malignancies. It is unknown if BV use affects procurement of autologous CD34(+) stem cells and hematopoietic engraftment after autologous stem cell transplantation (ASCT). We examined 42 patients treated with BV before mobilization. Median times from diagnosis to transplantation, from initial BV treatment to transplantation, and from last BV treatment to stem cell collection were 21 months (range, 10 to 210), 5 months (range, 1.5 to 16.8), and 30 days (range, 2 to 280), respectively. Mobilization was successful on the first attempt in 38 patients (90.4%). The median number of infused CD34(+) cells was 5.46 × 10(6)/kg (range, 1.65 to 54.78 × 10(6)/kg). The median times to neutrophil and platelet engraftment were 10 (range, 9 to 13), and 10.5 days (range, 7 to 35), respectively. BV before high-dose chemotherapy-ASCT did not adversely affect peripheral blood stem cell mobilization and subsequent engraftment in a cohort of heavily pretreated patients with CD30(+) lymphomas." @default.
• W2087533562 created "2016-06-24" @default.
• W2087533562 creator A5013926915 @default.
• W2087533562 creator A5016048836 @default.
• W2087533562 creator A5019470085 @default.
• W2087533562 creator A5029237145 @default.
• W2087533562 creator A5033737136 @default.
• W2087533562 creator A5034264716 @default.
• W2087533562 creator A5042915360 @default.
• W2087533562 creator A5048913229 @default.
• W2087533562 creator A5050962913 @default.
• W2087533562 creator A5064150576 @default.
• W2087533562 creator A5066894053 @default.
• W2087533562 creator A5083279961 @default.
• W2087533562 creator A5086276199 @default.
• W2087533562 date "2015-08-01" @default.
• W2087533562 modified "2023-09-27" @default.
• W2087533562 title "Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30+ Lymphoma Patients Who Received Multiple Prior Lines of Treatment" @default.
• W2087533562 cites W1598026308 @default.
• W2087533562 cites W1881943990 @default.
• W2087533562 cites W1969881698 @default.
• W2087533562 cites W1994835238 @default.
• W2087533562 cites W2008510614 @default.
• W2087533562 cites W2011118089 @default.
• W2087533562 cites W2029343747 @default.
• W2087533562 cites W2034794564 @default.
• W2087533562 cites W2036985459 @default.
• W2087533562 cites W2044365441 @default.
• W2087533562 cites W2051497664 @default.
• W2087533562 cites W2061337936 @default.
• W2087533562 cites W2066206878 @default.
• W2087533562 cites W2077455775 @default.
• W2087533562 cites W2115342159 @default.
• W2087533562 cites W2133201432 @default.
• W2087533562 cites W2133967407 @default.
• W2087533562 cites W2139891818 @default.
• W2087533562 cites W2146701863 @default.
• W2087533562 cites W2155256323 @default.
• W2087533562 cites W2157514847 @default.
• W2087533562 cites W2157717016 @default.
• W2087533562 cites W2266446519 @default.
• W2087533562 doi "https://doi.org/10.1016/j.bbmt.2015.04.022" @default.
• W2087533562 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4830276" @default.
• W2087533562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25937397" @default.
• W2087533562 hasPublicationYear "2015" @default.
• W2087533562 type Work @default.
• W2087533562 sameAs 2087533562 @default.
• W2087533562 citedByCount "4" @default.
• W2087533562 countsByYear W20875335622017 @default.
• W2087533562 countsByYear W20875335622019 @default.
• W2087533562 countsByYear W20875335622020 @default.
• W2087533562 crossrefType "journal-article" @default.
• W2087533562 hasAuthorship W2087533562A5013926915 @default.
• W2087533562 hasAuthorship W2087533562A5016048836 @default.
• W2087533562 hasAuthorship W2087533562A5019470085 @default.
• W2087533562 hasAuthorship W2087533562A5029237145 @default.
• W2087533562 hasAuthorship W2087533562A5033737136 @default.
• W2087533562 hasAuthorship W2087533562A5034264716 @default.
• W2087533562 hasAuthorship W2087533562A5042915360 @default.
• W2087533562 hasAuthorship W2087533562A5048913229 @default.
• W2087533562 hasAuthorship W2087533562A5050962913 @default.
• W2087533562 hasAuthorship W2087533562A5064150576 @default.
• W2087533562 hasAuthorship W2087533562A5066894053 @default.
• W2087533562 hasAuthorship W2087533562A5083279961 @default.
• W2087533562 hasAuthorship W2087533562A5086276199 @default.
• W2087533562 hasBestOaLocation W20875335621 @default.
• W2087533562 hasConcept C10205521 @default.
• W2087533562 hasConcept C126322002 @default.
• W2087533562 hasConcept C129470790 @default.
• W2087533562 hasConcept C13373296 @default.
• W2087533562 hasConcept C141071460 @default.
• W2087533562 hasConcept C143998085 @default.
• W2087533562 hasConcept C170493617 @default.
• W2087533562 hasConcept C201750760 @default.
• W2087533562 hasConcept C203014093 @default.
• W2087533562 hasConcept C2776694085 @default.
• W2087533562 hasConcept C2777408962 @default.
• W2087533562 hasConcept C2778191690 @default.
• W2087533562 hasConcept C2778828106 @default.
• W2087533562 hasConcept C2779050716 @default.
• W2087533562 hasConcept C2779338263 @default.
• W2087533562 hasConcept C28328180 @default.
• W2087533562 hasConcept C2911091166 @default.
• W2087533562 hasConcept C54355233 @default.
• W2087533562 hasConcept C70905583 @default.
• W2087533562 hasConcept C71924100 @default.
• W2087533562 hasConcept C86803240 @default.
• W2087533562 hasConcept C90924648 @default.
• W2087533562 hasConceptScore W2087533562C10205521 @default.
• W2087533562 hasConceptScore W2087533562C126322002 @default.
• W2087533562 hasConceptScore W2087533562C129470790 @default.
• W2087533562 hasConceptScore W2087533562C13373296 @default.
• W2087533562 hasConceptScore W2087533562C141071460 @default.
• W2087533562 hasConceptScore W2087533562C143998085 @default.
• W2087533562 hasConceptScore W2087533562C170493617 @default.
• W2087533562 hasConceptScore W2087533562C201750760 @default.
• W2087533562 hasConceptScore W2087533562C203014093 @default.
• W2087533562 hasConceptScore W2087533562C2776694085 @default.
• W2087533562 hasConceptScore W2087533562C2777408962 @default.
• W2087533562 hasConceptScore W2087533562C2778191690 @default.

• next